high complexity diagnostics at the point-of-need. bridging the gap between discovery and delivery at slipchip we integrate high-complexity laboratory assays, into an easy to perform, affordable and accessible sample-to-answer format across a wide range of environments. what if physicians could make rapid, individualized optimal treatment decisions? today, patients are often forced to endure days of waiting for lab results. as a result, doctors initially treat everyone with a strong cocktail of drugs. this approach is costly and can be harmful to patients.it also leads to serious drug resistance problems. our technology will allow doctors to provide optimal therapies to patients sooner. empowering physicians to make informed treatment decisions quickly. minimizing risks and reducing patient recovery times.
Company profile
Ticker
TLIS
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
SlipChip Corp
SEC CIK
TLIS stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
11 Apr 24
EFFECT
Notice of effectiveness
1 Apr 24
10-K
2023 FY
Annual report
28 Mar 24
POS AM
Prospectus update (post-effective amendment)
26 Mar 24
8-K
Departure of Directors or Certain Officers
26 Jan 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
Talis Biomedical Announces Exploration of Strategic Alternatives and Cost Reduction Plan to Preserve Cash
14 Nov 23
8-K
Departure of Directors or Certain Officers
1 Sep 23
S-8
Registration of securities for employees
10 Aug 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
Transcripts
TLIS
Earnings call transcript
2023 Q2
10 Aug 23
TLIS
Earnings call transcript
2023 Q1
11 May 23
TLIS
Earnings call transcript
2022 Q2
5 Aug 22
TLIS
Earnings call transcript
2022 Q1
15 May 22
TLIS
Earnings call transcript
2021 Q4
16 Mar 22
TLIS
Earnings call transcript
2021 Q3
16 Nov 21
TLIS
Earnings call transcript
2021 Q2
11 Aug 21
TLIS
Earnings call transcript
2021 Q1
12 May 21
Latest ownership filings
SC 13G/A
GREENLIGHT CAPITAL INC
14 Feb 24
4
Andrew A Lukowiak
2 Aug 23
3
Andrew A Lukowiak
2 Aug 23
4
Rebecca Markovich
18 Jul 23
4
JULIAN BAKER
13 Jun 23
4
Randal W. Scott
12 Jun 23
4
Matthew L. Posard
12 Jun 23
4
Kimberly J Popovits
12 Jun 23
4
Melissa Gilliam
12 Jun 23
4
Rustem F. Ismagilov
12 Jun 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 89.54 mm | 89.54 mm | 89.54 mm | 89.54 mm | 89.54 mm | 89.54 mm |
Cash burn (monthly) | 3.74 mm | 4.67 mm | 5.66 mm | 6.71 mm | 3.71 mm | 4.62 mm |
Cash used (since last report) | 25.49 mm | 31.83 mm | 38.57 mm | 45.72 mm | 25.33 mm | 31.49 mm |
Cash remaining | 64.05 mm | 57.71 mm | 50.97 mm | 43.82 mm | 64.21 mm | 58.05 mm |
Runway (months of cash) | 17.1 | 12.4 | 9.0 | 6.5 | 17.3 | 12.6 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 21 |
Opened positions | 4 |
Closed positions | 4 |
Increased positions | 3 |
Reduced positions | 6 |
13F shares | Current |
---|---|
Total value | 5.25 bn |
Total shares | 10.98 mm |
Total puts | 0.00 |
Total calls | 27.90 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Baker Bros. Advisors | 7.62 mm | $3.66 bn |
Greenlight Capital | 2.24 mm | $1.07 bn |
Vanguard | 466.34 k | $223.84 mm |
Geode Capital Management | 140.53 k | $67.45 mm |
Millennium Management | 91.46 k | $43.90 mm |
BLK Blackrock | 76.31 k | $36.63 mm |
MS Morgan Stanley | 61.86 k | $29.69 mm |
Renaissance Technologies | 54.90 k | $26.00 k |
Two Sigma Securities | 49.01 k | $23.52 mm |
STT State Street | 47.44 k | $22.77 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Aug 23 | Andrew A Lukowiak | Stock option Common Stock | Grant | Acquire A | No | No | 7.42 | 30,575 | 226.87 k | 30,575 |
17 Jul 23 | Rebecca Markovich | Stock option Common Stock | Grant | Acquire A | No | No | 7.65 | 13,071 | 99.99 k | 13,071 |
9 Jun 23 | Baker Bros. Advisors | Non- Qualified Stock Option Common Stock | Grant | Acquire A | Yes | No | 0.5047 | 23,685 | 11.95 k | 23,685 |
9 Jun 23 | Baker Bros. Advisors | Non- Qualified Stock Option Common Stock | Grant | Acquire A | Yes | No | 0.5047 | 23,685 | 11.95 k | 23,685 |
9 Jun 23 | Heiner Dreismann | Stock option Common Stock | Grant | Acquire A | No | No | 0.5 | 5,466 | 2.73 k | 5,466 |